



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

MEDICINES RECOMMENDED FOR INCLUSION IN THE PHILIPPINE NATIONAL FORMULARY (PNF)

As of 09 August 2021, the Health Technology Assessment Council (HTAC) has finished the assessment and deliberation on **Tenofovir/Lamivudine/Dolutegravir (TLD) for treatment-naive and treatment-experienced adolescents and adults living with HIV**. The evaluation aims to appraise existing relevant information on (a) Clinical effectiveness and safety; (b) Economic/Budget impact; (c) Responsiveness to Disease Magnitude, Severity, and Equity; (d) Safety and Effectiveness; (e) Household Financial Impact; and (f) Cost-effectiveness; (g) Affordability & Viability.

The HTAC hereby makes public the **preliminary recommendation for the inclusion of Tenofovir/Lamivudine/Dolutegravir (TLD)** attached in the Evidence Summary with supporting studies informing their recommendation. All comments, inputs and/or appeals may be submitted until **23 August 2021** for consideration of the HTAC through email at hta@doh.gov.ph.

Should you wish to submit hard copies of your submissions, you may drop them off at the 4th floor, Philippine Blood Disease and Transfusion Center, Lung Center Compound, Quezon Avenue, Quezon Avenue, Quezon City. Appeals shall no longer be entertained after the prescribed deadline.

A handwritten signature in black ink, appearing to read "Anna M. Guerrero", is written over the typed name and title.

ANNA MELISSA S. GUERRERO, MD, MPH (HTA)
Head, Health Technology Assessment Unit
Health Regulation Team